0000000000725246
AUTHOR
Sarah Hershko
What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects
Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short…
SUPPLEMENTARY_MATERIAL_A._WORLDWIDE_CT_ANALYSIS-v2.xlsx – Supplemental material for What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects
Supplemental material, SUPPLEMENTARY_MATERIAL_A._WORLDWIDE_CT_ANALYSIS-v2.xlsx for What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects by Isabel Fambuena-Muedra, Marta Jiménez-García, Sarah Hershko, Irene Altemir-Gómez and Ana Tobarra-López in European Journal of Ophthalmology